Doctors are being warned against prescribing romosozumab in patients with a history of MI or stroke following a TGA investigation into the cardiovascular risks of the potent osteoporosis drug.

The product information (PI) for romosozumab (Evenity) has been updated to include a special warning for prescribers to consider a patient’s fracture and cardiovascular risks in tandem.

“Monitor for signs and symptoms of [MI] and stroke and instruct patients to seek prompt medical attention if symptoms occur,” the PI states.

“If a patient experiences [an MI] or stroke during therapy, Evenity treatment should be discontinued.”